← Eichor
Study identifier: NCT05381194 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

BPaL(M) Regimen for the Treatment of MDR/RR-TB

Condition: Multidrug- and Rifampicin-resistant Tuberculosis  ·  Sponsor: Asan Medical Center

PhasePhase 4
Planned participants80
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

The objective of this study is to analyze the efficacy of a new regimen using Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 24 weeks or Bedaquiline, Pretomanid, Linezolid for 26 weeks for the treatment of MDR/RR-TB through the clinical trial.

This description comes directly from the study's public registry record.

Talk to the study team

Tae Sun Shim, MD, PhD  ·  +82-2-3010-3892  ·  shimts@amc.seoul.kr

Always discuss trial participation with your own doctor first.

Locations (1)

Asan Medical CenterSeoul, Songpa-gu, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05381194